NATURE . COM {}

Matching Content Categories {📚}

• Education
• Science
• Telecommunications

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}

Display Ads {🎯}

Direct Advertisers (10)

Reseller Advertisers (38)

How Much Does Nature.com Make? {💰}

Display Ads {🎯}

$536,300 per month
Estimations show Nature.com's display ad online revenue falls between $357,503 and $983,134 per month.

Keywords {🔍}

data, article, cell, nature, merck, manuscript, research, renal, carcinoma, patients, google, scholar, study, cancer, therapeutics, provided, analysis, received, approval, cas, access, sharp, dohme, contributed, interpretation, drafting, revising, final, submit, publication, daily, belzutifan, clinical, usa, pfizer, hypoxiainducible, hifα, clear, funding, provision, content, msd, subsidiary, privacy, information, medicine, ccrcc, design, oncology, acquisition,

Topics {✒️}

3-difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzo nitrile nature portfolio journals permissions reprints nature portfolio advertising analysis portal privacy policy dana–farber cancer institute author information authors social media hypoxia-inducible factor-2α hypoxia-inducible factor 2α metastatic renal-cell carcinoma nature+ nature kidney cancer research von hippel-lindau disease median progression-free survival hypoxia-inducible factor-2 product development immune checkpoint inhibitors heavily pre-treated patients author correction dose-limiting toxicities occurred data privacy legislation renal cell carcinoma received research funding policy compliance real-world pharmacovigilance study adverse event management reporting summary rights digestive system cancers anti-tumor activity hypoxia-inducible factors permissions national cancer institute scientific validity editor recognition statement clinical care options springerlink instant access kidney cancer armamentarium research funding cell death dis small-molecule antagonist data sharing agreement extended data fig harvard medical school adverse event pittsburgh medical center cancer clinical trials

Questions {❓}

• A complex task?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
         description:Hypoxia-inducible factor-2α (HIF-2α) is a transcription factor that frequently accumulates in clear cell renal cell carcinoma (ccRCC), resulting in constitutive activation of genes involved in carcinogenesis. Belzutifan (MK-6482, previously known as PT2977) is a potent, selective small molecule inhibitor of HIF-2α. Maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of belzutifan were evaluated in this first-in-human phase 1 study (NCT02974738). Patients had advanced solid tumors (dose-escalation cohort) or previously treated advanced ccRCC (dose-expansion cohort). Belzutifan was administered orally using a 3 + 3 dose-escalation design, followed by expansion at the recommended phase 2 dose (RP2D) in patients with ccRCC. In the dose-escalation cohort (n = 43), no dose-limiting toxicities occurred at doses up to 160 mg once daily, and the maximum tolerated dose was not reached; the RP2D was 120 mg once daily. Plasma erythropoietin reductions were observed at all doses; erythropoietin concentrations correlated with plasma concentrations of belzutifan. In patients with ccRCC who received 120 mg once daily (n = 55), the confirmed objective response rate was 25% (all partial responses), and the median progression-free survival was 14.5 months. The most common grade ≥3 adverse events were anemia (27%) and hypoxia (16%). Belzutifan was well tolerated and demonstrated preliminary anti-tumor activity in heavily pre-treated patients, suggesting that HIF-2α inhibition might offer an effective treatment for ccRCC. A first-in-human trial of hypoxia-inducible factor (HIF)-2α inhibitor belzutifan (MK-6482) has a favorable safety profile and shows promising clinical activity for the treatment of patients with renal cell carcinoma who have been heavily pre-treated.
         datePublished:2021-04-22T00:00:00Z
         dateModified:2021-08-27T00:00:00Z
         pageStart:802
         pageEnd:805
         sameAs:https://doi.org/10.1038/s41591-021-01324-7
         keywords:
            Renal cancer
            Targeted therapies
            Biomedicine
            general
            Cancer Research
            Metabolic Diseases
            Infectious Diseases
            Molecular Medicine
            Neurosciences
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01324-7/MediaObjects/41591_2021_1324_Fig1_HTML.png
         isPartOf:
            name:Nature Medicine
            issn:
               1546-170X
               1078-8956
            volumeNumber:27
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Toni K. Choueiri
               url:http://orcid.org/0000-0002-9201-3217
               affiliation:
                     name:Dana-Farber Cancer Institute and Harvard Medical School
                     address:
                        name:Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Todd M. Bauer
               affiliation:
                     name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC
                     address:
                        name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kyriakos P. Papadopoulos
               affiliation:
                     name:South Texas Accelerated Research Therapeutics (START)
                     address:
                        name:South Texas Accelerated Research Therapeutics (START), San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elizabeth R. Plimack
               url:http://orcid.org/0000-0002-7618-0744
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jaime R. Merchan
               affiliation:
                     name:University of Miami
                     address:
                        name:University of Miami, Miami, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David F. McDermott
               url:http://orcid.org/0000-0002-2675-5095
               affiliation:
                     name:Beth Israel Deaconess Medical Center
                     address:
                        name:Beth Israel Deaconess Medical Center, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Dror Michaelson
               url:http://orcid.org/0000-0001-9249-6338
               affiliation:
                     name:Massachusetts General Hospital
                     address:
                        name:Massachusetts General Hospital, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Leonard J. Appleman
               affiliation:
                     name:University of Pittsburgh Medical Center
                     address:
                        name:University of Pittsburgh Medical Center, Pittsburgh, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sanjay Thamake
               affiliation:
                     name:Merck & Co., Inc
                     address:
                        name:Merck & Co., Inc, Kenilworth, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rodolfo F. Perini
               affiliation:
                     name:Merck & Co., Inc
                     address:
                        name:Merck & Co., Inc, Kenilworth, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Naseem J. Zojwalla
               affiliation:
                     name:Merck & Co., Inc
                     address:
                        name:Merck & Co., Inc, Kenilworth, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eric Jonasch
               url:http://orcid.org/0000-0003-0943-2806
               affiliation:
                     name:The University of Texas MD Anderson Cancer Center
                     address:
                        name:The University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
      description:Hypoxia-inducible factor-2α (HIF-2α) is a transcription factor that frequently accumulates in clear cell renal cell carcinoma (ccRCC), resulting in constitutive activation of genes involved in carcinogenesis. Belzutifan (MK-6482, previously known as PT2977) is a potent, selective small molecule inhibitor of HIF-2α. Maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of belzutifan were evaluated in this first-in-human phase 1 study (NCT02974738). Patients had advanced solid tumors (dose-escalation cohort) or previously treated advanced ccRCC (dose-expansion cohort). Belzutifan was administered orally using a 3 + 3 dose-escalation design, followed by expansion at the recommended phase 2 dose (RP2D) in patients with ccRCC. In the dose-escalation cohort (n = 43), no dose-limiting toxicities occurred at doses up to 160 mg once daily, and the maximum tolerated dose was not reached; the RP2D was 120 mg once daily. Plasma erythropoietin reductions were observed at all doses; erythropoietin concentrations correlated with plasma concentrations of belzutifan. In patients with ccRCC who received 120 mg once daily (n = 55), the confirmed objective response rate was 25% (all partial responses), and the median progression-free survival was 14.5 months. The most common grade ≥3 adverse events were anemia (27%) and hypoxia (16%). Belzutifan was well tolerated and demonstrated preliminary anti-tumor activity in heavily pre-treated patients, suggesting that HIF-2α inhibition might offer an effective treatment for ccRCC. A first-in-human trial of hypoxia-inducible factor (HIF)-2α inhibitor belzutifan (MK-6482) has a favorable safety profile and shows promising clinical activity for the treatment of patients with renal cell carcinoma who have been heavily pre-treated.
      datePublished:2021-04-22T00:00:00Z
      dateModified:2021-08-27T00:00:00Z
      pageStart:802
      pageEnd:805
      sameAs:https://doi.org/10.1038/s41591-021-01324-7
      keywords:
         Renal cancer
         Targeted therapies
         Biomedicine
         general
         Cancer Research
         Metabolic Diseases
         Infectious Diseases
         Molecular Medicine
         Neurosciences
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01324-7/MediaObjects/41591_2021_1324_Fig1_HTML.png
      isPartOf:
         name:Nature Medicine
         issn:
            1546-170X
            1078-8956
         volumeNumber:27
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Toni K. Choueiri
            url:http://orcid.org/0000-0002-9201-3217
            affiliation:
                  name:Dana-Farber Cancer Institute and Harvard Medical School
                  address:
                     name:Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Todd M. Bauer
            affiliation:
                  name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC
                  address:
                     name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kyriakos P. Papadopoulos
            affiliation:
                  name:South Texas Accelerated Research Therapeutics (START)
                  address:
                     name:South Texas Accelerated Research Therapeutics (START), San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elizabeth R. Plimack
            url:http://orcid.org/0000-0002-7618-0744
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jaime R. Merchan
            affiliation:
                  name:University of Miami
                  address:
                     name:University of Miami, Miami, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David F. McDermott
            url:http://orcid.org/0000-0002-2675-5095
            affiliation:
                  name:Beth Israel Deaconess Medical Center
                  address:
                     name:Beth Israel Deaconess Medical Center, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Dror Michaelson
            url:http://orcid.org/0000-0001-9249-6338
            affiliation:
                  name:Massachusetts General Hospital
                  address:
                     name:Massachusetts General Hospital, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Leonard J. Appleman
            affiliation:
                  name:University of Pittsburgh Medical Center
                  address:
                     name:University of Pittsburgh Medical Center, Pittsburgh, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sanjay Thamake
            affiliation:
                  name:Merck & Co., Inc
                  address:
                     name:Merck & Co., Inc, Kenilworth, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rodolfo F. Perini
            affiliation:
                  name:Merck & Co., Inc
                  address:
                     name:Merck & Co., Inc, Kenilworth, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Naseem J. Zojwalla
            affiliation:
                  name:Merck & Co., Inc
                  address:
                     name:Merck & Co., Inc, Kenilworth, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eric Jonasch
            url:http://orcid.org/0000-0003-0943-2806
            affiliation:
                  name:The University of Texas MD Anderson Cancer Center
                  address:
                     name:The University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Medicine
      issn:
         1546-170X
         1078-8956
      volumeNumber:27
Organization:
      name:Nature Publishing Group US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dana-Farber Cancer Institute and Harvard Medical School
      address:
         name:Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC
      address:
         name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA
         type:PostalAddress
      name:South Texas Accelerated Research Therapeutics (START)
      address:
         name:South Texas Accelerated Research Therapeutics (START), San Antonio, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:University of Miami
      address:
         name:University of Miami, Miami, USA
         type:PostalAddress
      name:Beth Israel Deaconess Medical Center
      address:
         name:Beth Israel Deaconess Medical Center, Boston, USA
         type:PostalAddress
      name:Massachusetts General Hospital
      address:
         name:Massachusetts General Hospital, Boston, USA
         type:PostalAddress
      name:University of Pittsburgh Medical Center
      address:
         name:University of Pittsburgh Medical Center, Pittsburgh, USA
         type:PostalAddress
      name:Merck & Co., Inc
      address:
         name:Merck & Co., Inc, Kenilworth, USA
         type:PostalAddress
      name:Merck & Co., Inc
      address:
         name:Merck & Co., Inc, Kenilworth, USA
         type:PostalAddress
      name:Merck & Co., Inc
      address:
         name:Merck & Co., Inc, Kenilworth, USA
         type:PostalAddress
      name:The University of Texas MD Anderson Cancer Center
      address:
         name:The University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Toni K. Choueiri
      url:http://orcid.org/0000-0002-9201-3217
      affiliation:
            name:Dana-Farber Cancer Institute and Harvard Medical School
            address:
               name:Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Todd M. Bauer
      affiliation:
            name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC
            address:
               name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA
               type:PostalAddress
            type:Organization
      name:Kyriakos P. Papadopoulos
      affiliation:
            name:South Texas Accelerated Research Therapeutics (START)
            address:
               name:South Texas Accelerated Research Therapeutics (START), San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Elizabeth R. Plimack
      url:http://orcid.org/0000-0002-7618-0744
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Jaime R. Merchan
      affiliation:
            name:University of Miami
            address:
               name:University of Miami, Miami, USA
               type:PostalAddress
            type:Organization
      name:David F. McDermott
      url:http://orcid.org/0000-0002-2675-5095
      affiliation:
            name:Beth Israel Deaconess Medical Center
            address:
               name:Beth Israel Deaconess Medical Center, Boston, USA
               type:PostalAddress
            type:Organization
      name:M. Dror Michaelson
      url:http://orcid.org/0000-0001-9249-6338
      affiliation:
            name:Massachusetts General Hospital
            address:
               name:Massachusetts General Hospital, Boston, USA
               type:PostalAddress
            type:Organization
      name:Leonard J. Appleman
      affiliation:
            name:University of Pittsburgh Medical Center
            address:
               name:University of Pittsburgh Medical Center, Pittsburgh, USA
               type:PostalAddress
            type:Organization
      name:Sanjay Thamake
      affiliation:
            name:Merck & Co., Inc
            address:
               name:Merck & Co., Inc, Kenilworth, USA
               type:PostalAddress
            type:Organization
      name:Rodolfo F. Perini
      affiliation:
            name:Merck & Co., Inc
            address:
               name:Merck & Co., Inc, Kenilworth, USA
               type:PostalAddress
            type:Organization
      name:Naseem J. Zojwalla
      affiliation:
            name:Merck & Co., Inc
            address:
               name:Merck & Co., Inc, Kenilworth, USA
               type:PostalAddress
            type:Organization
      name:Eric Jonasch
      url:http://orcid.org/0000-0003-0943-2806
      affiliation:
            name:The University of Texas MD Anderson Cancer Center
            address:
               name:The University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
      name:Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA
      name:South Texas Accelerated Research Therapeutics (START), San Antonio, USA
      name:Fox Chase Cancer Center, Philadelphia, USA
      name:University of Miami, Miami, USA
      name:Beth Israel Deaconess Medical Center, Boston, USA
      name:Massachusetts General Hospital, Boston, USA
      name:University of Pittsburgh Medical Center, Pittsburgh, USA
      name:Merck & Co., Inc, Kenilworth, USA
      name:Merck & Co., Inc, Kenilworth, USA
      name:Merck & Co., Inc, Kenilworth, USA
      name:The University of Texas MD Anderson Cancer Center, Houston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

• https://www.facebook.com/Nature-Medicine-193691346949/
• https://twitter.com/naturemedicine

External Links {🔗}(84)

• How much income does https://orcid.org/0000-0002-9201-3217 have?
• Learn about the earnings of https://orcid.org/0000-0002-7618-0744
• How much profit does https://orcid.org/0000-0002-2675-5095 make?
• How much does https://orcid.org/0000-0001-9249-6338 pull in monthly?
• How much revenue does https://orcid.org/0000-0003-0943-2806 generate?
• Check the income stats for https://doi.org/10.1038/s41591-021-01516-1
• How much does https://link.springer.com/article/10.1038/s41591-021-01324-7?utm_source=nature&utm_medium=referral&utm_campaign=buyArticle generate monthly?
• How much does http://engagezone.msd.com/ds_documentation.php gross monthly?
• Financial intake of https://doi.org/10.1056%2FNEJMra1601333
• How much cash flow does http://scholar.google.com/scholar_lookup?&title=Systemic%20therapy%20for%20metastatic%20renal-cell%20carcinoma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMra1601333&volume=376&pages=354-366&publication_year=2017&author=Choueiri%2CTK&author=Motzer%2CRJ have monthly?
• What's https://doi.org/10.1038%2Fs41585-019-0211-5's gross income?
• How much does http://scholar.google.com/scholar_lookup?&title=The%20cancer%20genome%20atlas%20of%20renal%20cell%20carcinoma%3A%20findings%20and%20clinical%20implications&journal=Nat.%20Rev.%20Urol.&doi=10.1038%2Fs41585-019-0211-5&volume=16&pages=539-552&publication_year=2019&author=Linehan%2CWM&author=Ricketts%2CCJ earn?
• See how much http://scholar.google.com/scholar_lookup?&title=Targeting%20the%20HIF2%E2%80%93VEGF%20axis%20in%20renal%20cell%20carcinoma&journal=Nat.%20Med.&volume=5&pages=1-2&publication_year=2020&author=Choueiri%2CTK&author=Kaelin%2CWG makes per month
• How much does https://doi.org/10.1371%2Fjournal.pbio.0000083 bring in each month?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Inhibition%20of%20HIF2%CE%B1%20is%20sufficient%20to%20suppress%20pVHL-defective%20tumor%20growth&journal=PLoS%20Biol.&doi=10.1371%2Fjournal.pbio.0000083&volume=1&publication_year=2003&author=Kondo%2CK&author=Kim%2CWY&author=Lechpammer%2CM&author=Kaelin%2CWG
• How much profit is https://doi.org/10.1016%2Fj.blre.2012.12.003 making per month?
• Financial intake of http://scholar.google.com/scholar_lookup?&title=Regulation%20of%20erythropoiesis%20by%20hypoxia-inducible%20factors&journal=Blood%20Rev.&doi=10.1016%2Fj.blre.2012.12.003&volume=27&pages=41-53&publication_year=2013&author=Haase%2CVH
• Discover the revenue of https://doi.org/10.1038%2Fcddis.2014.565
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20hypoxia-inducible%20factor-2%20in%20digestive%20system%20cancers&journal=Cell%20Death%20Dis.&doi=10.1038%2Fcddis.2014.565&volume=6&publication_year=2015&author=Zhao%2CJ&author=Du%2CF&author=Shen%2CG&author=Zheng%2CF&author=Xu%2CB
• See how much https://doi.org/10.1016%2Fj.drudis.2019.09.008 makes per month
• How much money does http://scholar.google.com/scholar_lookup?&title=Allosteric%20inhibition%20of%20HIF-2%CE%B1%20as%20a%20novel%20therapy%20for%20clear%20cell%20renal%20cell%20carcinoma&journal=Drug%20Discov.%20Today&doi=10.1016%2Fj.drudis.2019.09.008&volume=24&pages=2332-2340&publication_year=2019&author=Yu%2CY&author=Yu%2CQ&author=Zhang%2CX generate?
• What's the income generated by https://doi.org/10.1200%2FJCO.2017.74.2627 each month?
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Phase%20I%20dose-escalation%20trial%20of%20PT2385%2C%20a%20first-in-class%20hypoxia-inducible%20factor-2%CE%B1%20antagonist%20in%20patients%20with%20previously%20treated%20advanced%20clear%20cell%20renal%20cell%20carcinoma&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2017.74.2627&volume=36&pages=867-874&publication_year=2018&author=Courtney%2CKD is on a monthly basis
• What's the income of https://doi.org/10.1200%2FJCO.2017.77.5254?
• How much does http://scholar.google.com/scholar_lookup?&title=HIF2%20inhibitor%20joins%20the%20kidney%20cancer%20armamentarium&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2017.77.5254&volume=36&pages=908-910&publication_year=2018&author=Kaelin%2CWG generate monthly?
• What is the earnings of https://doi.org/10.1158%2F0008-5472.CAN-16-0473?
• How much profit does http://scholar.google.com/scholar_lookup?&title=A%20small-molecule%20antagonist%20of%20HIF2%CE%B1%20is%20efficacious%20in%20preclinical%20models%20of%20renal%20cell%20carcinoma&journal=Cancer%20Res.&doi=10.1158%2F0008-5472.CAN-16-0473&volume=76&pages=5491-5500&publication_year=2016&author=Wallace%2CEM generate?
• What's the financial gain of https://doi.org/10.1634%2Ftheoncologist.2011-S2-32?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=Treatment-associated%20adverse%20event%20management%20in%20the%20advanced%20renal%20cell%20carcinoma%20patient%20treated%20with%20targeted%20therapies&journal=Oncologist&doi=10.1634%2Ftheoncologist.2011-S2-32&volume=16&pages=32-44&publication_year=2011&author=Ravaud%2CA
• How much does https://doi.org/10.1016%2Fj.semnephrol.2019.12.009 generate monthly?
• What are the total earnings of http://scholar.google.com/scholar_lookup?&title=Immune%20checkpoint%20inhibitors%20in%20the%20treatment%20of%20renal%20cell%20carcinoma&journal=Semin.%20Nephrol.&doi=10.1016%2Fj.semnephrol.2019.12.009&volume=40&pages=76-85&publication_year=2020&author=Parikh%2CM&author=Bajwa%2CP?
• How much does https://doi.org/10.1172%2FJCI30117 make?
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Hypoxia-inducible%20factor-2%20%28HIF-2%29%20regulates%20hepatic%20erythropoietin%20in%20vivo&journal=J.%20Clin.%20Invest.&doi=10.1172%2FJCI30117&volume=117&pages=1068-1077&publication_year=2007&author=Rankin%2CEB
• What's the monthly money flow for https://doi.org/10.1182%2Fblood-2004-05-1695?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=HIF-2%CE%B1%20regulates%20murine%20hematopoietic%20development%20in%20an%20erythropoietin-dependent%20manner&journal=Blood&doi=10.1182%2Fblood-2004-05-1695&volume=105&pages=3133-3140&publication_year=2005&author=Scortegagna%2CM?
• How much revenue does https://doi.org/10.1164%2Frccm.201710-2079OC bring in?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Therapeutic%20targeting%20of%20vascular%20remodeling%20and%20right%20heart%20failure%20in%20pulmonary%20arterial%20hypertension%20with%20a%20HIF-2%CE%B1%20inhibitor&journal=Am.%20J.%20Respir.%20Crit.%20Care%20Med.&doi=10.1164%2Frccm.201710-2079OC&volume=198&pages=1423-1434&publication_year=2018&author=Dai%2CZ
• What's https://doi.org/10.1016%2Fj.critrevonc.2017.01.013's gross income?
• What's the income of http://scholar.google.com/scholar_lookup?&title=Targeting%20HIF-2%20alpha%20in%20clear%20cell%20renal%20cell%20carcinoma%3A%20a%20promising%20therapeutic%20strategy&journal=Crit.%20Rev.%20Oncol.%20Hematol.&doi=10.1016%2Fj.critrevonc.2017.01.013&volume=111&pages=117-123&publication_year=2017&author=Martinez-Saez%2CO&author=Gajate%20Borau%2CP&author=Alonso-Gordoa%2CT&author=Molina-Cerrillo%2CJ&author=Grande%2CE?
• Earnings of https://doi.org/10.1016%2Fj.cbpa.2010.03.022
• Get to know http://scholar.google.com/scholar_lookup?&title=A%20complex%20task%3F%20Direct%20modulation%20of%20transcription%20factors%20with%20small%20molecules&journal=Curr.%20Opin.%20Chem.%20Biol.&doi=10.1016%2Fj.cbpa.2010.03.022&volume=14&pages=331-340&publication_year=2010&author=Koehler%2CAN's earnings
• What is the monthly revenue of https://doi.org/10.1097%2F00000421-198212000-00014?
• How much does http://scholar.google.com/scholar_lookup?&title=Toxicity%20and%20response%20criteria%20of%20the%20Eastern%20Cooperative%20Oncology%20Group&journal=Am.%20J.%20Clin.%20Oncol.&doi=10.1097%2F00000421-198212000-00014&volume=5&pages=649-655&publication_year=1982&author=Oken%2CMM pull in monthly?
• What's the financial outcome of https://doi.org/10.1093%2Fjnci%2Fdjp079?
• http://scholar.google.com/scholar_lookup?&title=Dose%20escalation%20methods%20in%20phase%20I%20cancer%20clinical%20trials&journal=J.%20Natl%20Cancer%20Inst.&doi=10.1093%2Fjnci%2Fdjp079&volume=101&pages=708-720&publication_year=2009&author=Tourneau%2CC&author=Lee%2CJJ&author=Siu%2CLL's total income per month
• How much income is https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01324-7?format=refman&flavour=references earning monthly?
• How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Toni%20K.%20Choueiri generate?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Toni%20K.%20Choueiri%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in each month?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Todd%20M.%20Bauer pull in monthly?
• What are the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Todd%20M.%20Bauer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kyriakos%20P.%20Papadopoulos bring in?
• Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kyriakos%20P.%20Papadopoulos%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Elizabeth%20R.%20Plimack earns monthly
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Elizabeth%20R.%20Plimack%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
• What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jaime%20R.%20Merchan?
• How profitable is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jaime%20R.%20Merchan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20F.%20McDermott
• What are the total earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20F.%20McDermott%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much profit is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M.%20Dror%20Michaelson making per month?
• What's the financial outcome of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M.%20Dror%20Michaelson%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Leonard%20J.%20Appleman
• What's the financial outcome of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Leonard%20J.%20Appleman%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sanjay%20Thamake's revenue stream
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sanjay%20Thamake%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rodolfo%20F.%20Perini gross monthly?
• What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rodolfo%20F.%20Perini%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Naseem%20J.%20Zojwalla?
• Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Naseem%20J.%20Zojwalla%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Eric%20Jonasch bring in each month?
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Eric%20Jonasch%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Check the income stats for https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01324-7/MediaObjects/41591_2021_1324_MOESM1_ESM.pdf
• How much does https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01324-7/MediaObjects/41591_2021_1324_MOESM2_ESM.pdf make?
• How much does https://s100.copyright.com/AppDispatchServlet?title=Inhibition%20of%20hypoxia-inducible%20factor-2%CE%B1%20in%20renal%20cell%20carcinoma%20with%20belzutifan%3A%20a%20phase%201%20trial%20and%20biomarker%20analysis&author=Toni%20K.%20Choueiri%20et%20al&contentID=10.1038%2Fs41591-021-01324-7©right=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Nature%20America%2C%20Inc.&publication=1078-8956&publicationDate=2021-04-22&publisherName=SpringerNature&orderBeanReset=true gross monthly?
• What's the income of https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-021-01324-7?
• How much profit does https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01324-7?format=refman&flavour=citation generate?
• Get to know what's the income of https://doi.org/10.1038/s41467-025-56955-y
• How much profit is https://doi.org/10.1038/s43018-025-00942-1 making per month?
• Explore the financials of https://doi.org/10.1007/s10142-025-01579-0
• How much cash flow does https://doi.org/10.1007/s11096-025-01953-9 have monthly?
• Earnings of https://doi.org/10.1007/s11864-024-01288-z
• What is the monthly revenue of https://www.protocols.io/?
• Financial intake of https://www.natureindex.com/
• What's the income of http://www.naturechina.com?
• Find out how much https://www.natureasia.com/ja-jp earns monthly

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Prism.js
• Zoom.js

Emails and Hosting {✉️}

Mail Servers:

• mxa-002c5801.gslb.pphosted.com
• mxb-002c5801.gslb.pphosted.com

Name Servers:

• pdns1.ultradns.net
• pdns2.ultradns.net
• pdns3.ultradns.org
• pdns4.ultradns.org
• pdns5.ultradns.info
• pdns6.ultradns.co.uk

CDN Services {📦}

• Crossref